Immunosuppressive agents modulate function, growth, and survival of cardiomyocytes and endothelial cells derived from human embryonic stem cells

Stem Cells and Development

Volumn 23, Issue 5, 2014, Pages 467-476

  Földes, Gábor ^a,b   Mioulane, Maxime ^a   Kodagoda, Thusharika ^a   Lendvai, Zsuzsanna ^b   Iqbal, Adeel ^a   Ali, Nadire N ^a   Schneider, Michael D ^a   Harding, Sian E ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CALCINEURIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLOSPORINE; EMBRYONIC STEM CELLS; ENDOTHELIAL CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCYTES, CARDIAC; OLIGOPEPTIDES; SIROLIMUS; STEM CELL TRANSPLANTATION; TACROLIMUS;

EID: 84894375203     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0229     Document Type: Article

References (38)

1. Lopez AD, CD Mathers, M Ezzati, DT Jamison and CJ Murray. (2006). Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 367:1747-1757.
2. He JQ, Y Ma, Y Lee, JA Thomson and TJ Kamp. (2003). Human embryonic stem cells develop into multiple types of cardiac myocytes: Action potential characterization. Circ Res 93:32-39.
3. Zhang J, GF Wilson, AG Soerens, CH Koonce, J Yu, SP Palecek, JA Thomson and TJ Kamp. (2009). Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104:e30-e41.
4. Levenberg S, JS Golub, M Amit, J Itskovitz-Eldor and R Langer. (2002). Endothelial cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 99:4391-4396.
5. Swijnenburg RJ, S Schrepfer, JA Govaert, F Cao, K Ransohoff, AY Sheikh, M Haddad, AJ Connolly, MM Davis, RC Robbins and JC Wu. (2008). Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A 105:12991-12996.
6. English K and KJ Wood. (2011). Immunogenicity of embryonic stem cell-derived progenitors after transplantation. Curr Opin Organ Transplant 16:90-95.
7. Zhao T, ZN Zhang, Z Rong and Y Xu. (2011). Immunogenicity of induced pluripotent stem cells. Nature 474: 212-215.
8. Guha P, JW Morgan, G Mostoslavsky, NP Rodrigues and AS Boyd. (2013). Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12:407-412.
9. Foldes G, M Mioulane, JS Wright, AQ Liu, P Novak, B Merkely, J Gorelik, MD Schneider, NN Ali and SE Harding. (2011). Modulation of human embryonic stem cell-derived cardiomyocyte growth: A testbed for studying human cardiac hypertrophy?. J Mol Cell Cardiol 50:367-376.
10. Noguchi H, M Matsushita, T Okitsu, A Moriwaki, K Tomizawa, S Kang, ST Li, N Kobayashi, S Matsumoto, et al. (2004). A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med 10:305-309.
11. Foldes G, A Liu, R Badiger, M Paul-Clark, L Moreno, Z Lendvai, JS Wright, NN Ali, SE Harding and JA Mitchell. (2010). Innate immunity in human embryonic stem cells: Comparison with adult human endothelial cells. PLoS One 5:e10501.
12. Lara-Pezzi E, N Winn, A Paul, K McCullagh, E Slominsky, MP Santini, F Mourkioti, P Sarathchandra, S Fukushima, K Suzuki and N Rosenthal. (2007). A naturally occurring calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration. J Cell Biol 179:1205-1218.
13. Iwai-Kanai E, K Hasegawa, M Araki, T Kakita, T Morimoto and S Sasayama. (1999). alpha-And beta-Adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 100:305-311.
14. Saito S, Y Hiroi, Y Zou, R Aikawa, H Toko, F Shibasaki, Y Yazaki, R Nagai and I Komuro. (2000). beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem 275:34528-34533.
15. Aramburu J, MB Yaffe, C Lopez-Rodriguez, LC Cantley, PG Hogan and A Rao. (1999). Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285:2129-2133.
16. Yamamoto S, K Seta, C Morisco, SF Vatner and J Sadoshima. (2001). Chelerythrine rapidly induces apoptosis through generation of reactive oxygen species in cardiac myocytes. J Mol Cell Cardiol 33:1829-1848.
17. Wilkins BJ and JD Molkentin. (2004). Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 322:1178-1191.
18. Zhao Y, G Hou, Y Zhang, J Chi, L Zhang, X Zou, J Tang, Y Liu, Y Fu and X Yin. (2011). Involvement of the calciumsensing receptor in cyclosporin A-induced cardiomyocyte apoptosis in rats. Pharmazie 66:968-974.
19. Altschuld RA, CM Hohl, LC Castillo, AA Garleb, RC Starling and GP Brierley. (1992). Cyclosporin inhibits mitochondrial calcium efflux in isolated adult rat ventricular cardiomyocytes. Am J Physiol 262:H1699-H1704.
20. Hong F, J Lee, JW Song, SJ Lee, H Ahn, JJ Cho, J Ha and SS Kim. (2002). Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolylcis-Trans isomerase activity of cyclophilin A: Cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity. FASEB J 16:1633-1635.
21. Elmore S. (2007). Apoptosis: A review of programmed cell death. Toxicol Pathol 35:495-516.
22. Cao F, RA Wagner, KD Wilson, X Xie, JD Fu, M Drukker, A Lee, RA Li, SS Gambhir, et al. (2008). Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One 3:e3474.
23. Kanter MM, RL Hamlin, DV Unverferth, HW Davis and AJ Merola. (1985). Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin. J Appl Physiol 59:1298-1303.
24. Rubinsztein DC, JE Gestwicki, LO Murphy and DJ Klionsky. (2007). Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6:304-312.
25. Barilli A, R Visigalli, R Sala, GC Gazzola, A Parolari, E Tremoli, S Bonomini, A Simon, EI Closs, V Dall'Asta and O Bussolati. (2008). In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res 78:563-571.
26. Griffiths EJ, CJ Ocampo, JS Savage, MD Stern and HS Silverman. (2000). Protective effects of low and high doses of cyclosporin A against reoxygenation injury in isolated rat cardiomyocytes are associated with differential effects on mitochondrial calcium levels. Cell Calcium 27:87-95.
27. Wan KF, SL Chan, SK Sukumaran, MC Lee and VC Yu. (2008). Chelerythrine induces apoptosis through a Bax/Bakindependent mitochondrial mechanism. J Biol Chem 283: 8423-8433.
28. Montaigne D, X Marechal, S Preau, R Baccouch, T Modine, G Fayad, S Lancel and R Neviere. (2011). Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion 11:22-26.
29. Alfaro MP, M Pagni, A Vincent, J Atkinson, MF Hill, J Cates, JM Davidson, J Rottman, E Lee and PP Young. (2008). The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci U S A 105:18366-18371.
30. Romano S, A Pace Di, A Sorrentino, R Bisogni, L Sivero and MF Romano. (2010). FK506 binding proteins as targets in anticancer therapy. Anticancer Agents Med Chem 10: 651-656.
31. Khan S, F Salloum, A Das, L Xi, GW Vetrovec and RC Kukreja. (2006). Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J Mol Cell Cardiol 41: 256-264.
32. Laflamme MA, KY Chen, AV Naumova, V Muskheli, JA Fugate, SK Dupras, H Reinecke, C Xu, M Hassanipour, et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 25:1015-1024.
33. Pearl JI, AS Lee, DB Leveson-Gower, N Sun, Z Ghosh, F Lan, J Ransohoff, RS Negrin, MM Davis and JC Wu. (2011). Shortterm immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 8:309-317.
34. Juhaszova M, DB Zorov, Y Yaniv, HB Nuss, S Wang and SJ Sollott. (2009). Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 104:1240-1252.
35. Sadoshima J and S Izumo. (1993). Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 73:424-438.
36. Pu WT, Q Ma and S Izumo. (2003). NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res 92:725-731.
37. Yano M, K Ono, T Ohkusa, M Suetsugu, M Kohno, T Hisaoka, S Kobayashi, Y Hisamatsu, T Yamamoto, et al. (2000). Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2 +) leak through ryanodine receptor in heart failure. Circulation 102:2131-2136.
38. Yu H, K Sliedregt-Bol, H Overkleeft, GA van der Marel, TJ van Berkel and EA Biessen. (2006). Therapeutic potential of a synthetic peptide inhibitor of nuclear factor of activated T cells as antirestenotic agent. Arterioscler Thromb Vasc Biol 26:1531-1537.